Tc 99m tilmanocept - Navidea Biopharmaceuticals
Alternative Names: Lymphoaim; Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Tc99m tilmanocept; Technetium Tc 99m tilmanocept; TilmanoceptLatest Information Update: 08 Aug 2024
At a glance
- Originator University of California, San Diego
- Developer Maimonides Medical Center; National Cancer Institute (USA); National Institute of Health Clinical Center; Navidea Biopharmaceuticals; Norgine; University of California, San Diego
- Class Heavy metals; Imaging agents; Radiopharmaceutical diagnostics; Technetium compounds
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Phase III Cardiovascular disorders; Rheumatoid arthritis
- Phase II Cervical cancer; Kaposi's sarcoma
- Clinical Phase Unknown Mouth neoplasm
- No development reported Colorectal cancer; Crohn's disease; Endometrial cancer; Liver metastases; Non-alcoholic steatohepatitis
Most Recent Events
- 25 Jul 2024 Navidea Biopharmaceuticals terminates a phase IIb trial in Rheumatoid arthritis (Diagnosis, In adults, In the elderly) in USA and the United Kingdom due to sponsor decision (Intradermal, Injection) (NCT04078191)
- 25 Jul 2024 Navidea Biopharmaceuticals terminates a phase III trial in Rheumatoid arthritis (Diagnosis, In adults, In the elderly) in USA due to sponsor decision (IV) (NCT05246280)
- 14 Jun 2023 Navidea Biopharmaceuticals entered into an amendment with Cardinal Health